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Abstract
Summary This review, endorsed by the International Osteoporosis Foundation and the European Society for Clinical and
Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, summarizes several failings of the recent guide-
lines of the American College of Physicians (ACP) on the treatment of low bone density or osteoporosis to prevent fractures.
Introduction The ACP recently issued guidelines for the treatment of low bone density or osteoporosis to prevent fractures.
Methods Literature review and critical review of the ACP guidelines.
Results The guideline is lacking in scope due to the endorsement of treatment based on T-scores rather than fracture risk
assessment and in failure to adequately consider anabolic therapies.
Conclusions The ACP guideline appears outdated.
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The American College of Physicians (ACP) recently issued
guidelines for the treatment of low bone density or osteopo-
rosis to prevent fractures [1]. ACP recommends that clinicians
offer pharmacological treatment to reduce spine and hip frac-
ture risk in women with osteoporosis, and consider treatment
in women at high risk. More specifically, ACP strongly rec-
ommends Bthat clinicians offer pharmacologic treatment with
alendronate, risedronate, zoledronic acid, or denosumab to
reduce the risk for hip and vertebral fractures in women who
have known osteoporosis.^
The recommendations are largely based on a systematic review
of randomized controlled trials. Whereas a review of such evi-
dence is to be commended, the guideline largely ignores other
important evidence that might modulate the way guidelines are
formulated [2–5]. The areas of concern discussed below include
the scope of guidelines, the position on FRAX, the limited dura-
tion of therapy, and the use of anabolic interventions.
Scope
Therestrictedscopeof theACPguidelines isexemplified in the title
that refers to treatment inmen andwomenwith osteoporosis. Two
definitions of osteoporosis are provided; one, theWHO definition
based on the T-score for bone mineral density and the other an
individual with a prior fragility fracture. Except for teriparatide
and raloxifene (not recommended as first-line treatments), the
ACPguideline considers that the evidence is insufficient to recom-
mend treatment of patients with prior fracture with other interven-
tions. Thus, the gateway to treatment is aBMDdiagnosis of osteo-
porosis though no recommendations are provided on who should
have a BMDmeasurement in the first place. The guideline fails in
the sense that there is no indication to whom they apply and no
reference to any relevant literature.
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The use of BMD as the exclusive gateway to assessment is
problematic for many reasons. Problems include the low sen-
sitivity of BMD for fracture prediction [6, 7], the different
significance of a given T-score according to age [8], and risks
that differ according to latitude [9] socioeconomic prosperity
[10] and country [11]. In many countries, intervention
thresholds, historically based on the T-score for BMD, have
been replaced in recent years by more complete risk assess-
ment tools that take account of the added weight of the risk
factors on fracture risk [12–16]. For example, 20 years ago,
the European Foundation for Osteoporosis (now the
International Osteoporosis Foundation) issued guidelines
for the diagnosis and management of osteoporosis [17], short-
ly followed by those of the Royal College of Physicians in the
UK [18]. Both organizations recommended treatment in pa-
tients with osteoporosis based on bone mineral density mea-
surements. Prospective patients to be referred for bone densi-
tometry were identified by the presence of clinical risk factors
associated with osteoporosis. The guidance utilized risk fac-
tors for fracture as an initial step for assessment, but recom-
mended treatment only in individuals with a T-score of − 2.5.
Guidelines in the UK [19, 20] and Europe [21, 22] and many
other countries [23] now accommodate FRAX as the primary
gateway to risk assessment. Others, including the USNational
Osteoporosis Foundation and American Association of
Clinical Endocrinologists include thresholds of fracture
risk [24, 25]. Against this shift, the ACP updated guidance,
firmly entrenching a T-score treatment threshold of − 2.5
SD, is reminiscent of European and UK guidance some
20 years ago [17, 18].
Review of FRAX
TheACPguidanceeschewstheuseofFRAXandstates that there is
noevidence fromrandomizedcontrol trialsdemonstratingabenefit
of fracture reduction when FRAX scores are used for treatment
decision-making. The argument implies that the beneficial effects
of treatment on fracture risk are restricted to patients with osteopo-
rosis. Irrespective of the veracity of the statement, the argument
presupposes that high FRAX scores with or without BMD do not
identify individuals with low bonemineral density—a supposition
that has for several years been shown tobe ill-founded [26–28].An
example of the application of the guidelines used by the National
Osteoporosis Guideline Group (NOGG) in the UK is given in
Table 1, which shows that the case-finding strategy (the use of
age-specific intervention thresholds) identifies women with low
BMD. Moreover, the conclusion that these drugs only act in
BMD-proven osteoporosis is a flawed one, driven by subgroup
analyses, most of which are post hoc [29]. Indeed, the relevant
question in amore statistically appropriate manner is as follows: is
there an interaction between the effect of treatment and baseline
BMD?All studies that have examined this for the outcome of ver-
tebral fractureshavenotshownanyimpactofbaselineBMDonrisk
reduction during therapy.
The ACP acknowledges that moderate-quality evidence from
post hoc analysis of 1 RCT showed no significant interaction be-
tween fracture risk as assessed by FRAXand the efficacy of ralox-
ifene for reducing the relative risk for vertebral fractures inwomen
older than75years. Itneglected to indicate thatsimilar findingsfora
majority of interventions used in osteoporosis including strontium
ranelate [30], raloxifene [31, 32], bazedoxifene [31], clodronate
[33], daily and weekly teriparatide [34, 35], abaloparatide [36],
denosumab[37]alendronate[38]aswellasabasketofinterventions
usedbygeneralpractitionersintheUK[39].Mostofthesewerepost
hoc but, in the case of denosumab, was a pre-planned analysis. In
addition, theBscreeningforpreventionoffracturesinolderwomen^
(SCOOP) study was a prospective randomized study that demon-
stratedefficacyforhipfracture inwomenselectedonthebasisofhip
fracture probability assessed using FRAX [39].
It is axiomatic that different intervention thresholds will
identify different patients at different risk. Some examples
are given in Table 2 based on the National Health and
Nutrition Examination Survey (NHANES) 2005–2008 [40,
Table 1 NOGG strategy applied
to women without prior fracture,















50 63 22 2 52 − 1.78
55 48 16 2 27 − 2.28
60 59 14 2 17 − 2.67
65 131 38 7 48 − 2.58
70 140 29 8 38 − 2.91
75 89 18 6 23 − 3.35
80 69 15 6 16 − 3.60
85 50 15 7 20 − 3.66
40 241
FN femoral neck,MOF major osteoporotic fracture (hip, clinical spine, forearm, and proximal humerus), NOGG
National Osteoporosis Guideline Group
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41]. It is of interest that the ACP guideline selects the greater
number of patients eligible for treatment than an age-specific
FRAX threshold, but the latter identifies a population at much
higher risk.
Limited duration of therapy
A serious deficit in the ACP guideline is that it recommends
that clinicians treat osteoporotic women with pharmacologic
therapy only for 5 years. Such a statement, based on low-
quality evidence, has very negative and potential dangerous
effects. The recommendation is based on an inadequate inter-
pretation of the long-term studies with bisphosphonates which
demonstrate that the incidence of non-vertebral fracture does
not differ between patients who continue or discontinue
alendronate or zoledronic acid after 5 and 3 years of therapy,
respectively [42, 43] The interpretation overlooks the fact that,
in the Fracture Intervention Trials with alendronate, there was
no significant effect of therapy on non-vertebral fracture risk
compared to placebo [44, 45] except in a subgroup of patients
with previous vertebral fractures or with hip BMD T-score
values ≤ − 2.5 [46]. Thus, if alendronate therapy does not re-
duce non-vertebral fracture risk in the overall set of patients, it
is hardly surprising that stopping treatment had no adverse
effect on non-vertebral fracture risk. In the case of zoledronic
acid after 3 years, the study was hopelessly underpowered to
elicit an effect of stopping treatment on this outcome. For both
alendronate and zoledronic acid, stopping treatment increases
the risk of vertebral fracture [42, 43], a finding that the ACP
guideline chose to ignore. The dangers of stopping treatment
are obfuscated by the long offset of action of the
bisphosphonates but more readily demonstrated with
denosumab. Cessation of treatment results in a rapid decrease
in bone mineral density and an increase in fracture rate [47–49],
whereas continuation of treatment has a progressive benefit for
Table 2 Number selected as
being above the intervention
threshold and the proportion who
will fracture over 10 years (mean
10-year fracture probability of
major osteoporotic fracture
(MOP) and hip fracture) in men
andwomen aged 50 years ormore
from the NHANES cohort ac-
cording to different intervention
thresholds [41], with kind per-
mission of John Wiley and Sons
Selection Men Women
% who fracture % who fracture
N MOF Hip N MOF Hip
None 1959 6.0 1.5 1649 10.2 2.4
FRAX fixed thresholdsa 266 13.5 6.3 387 21.2 7.9
FRAX at fracture thresholdb 54 16.3 4.0 144 26.0 9.7
FRAX fixed thresholds + prior fracturec 326 12.3 5.3 414 20.5 7.5
FRAX at fracture threshold + prior fracturec 121 11.9 2.9 179 23.4 8.2
NOFd 330 11.7 4.9 511 17.7 6.2
Prior fracturec 71 8.9 2.1 57 19.0 6.1
T-score ≤ − 2.5e 79 11.2 5.4 298 17.3 6.7
Prior fracture and T-score ≤ − 2.5e 148 9.9 3.6 335 17.0 6.4
a FRAX with 20 and 3% probability thresholds for major fracture and hip fracture respectively
b FRAX with age-specific thresholds equivalent to a woman with prior fracture
c Prior hip or spine fracture
d National Osteoporosis Foundation Guidelines [24]
e T-score at proximal femur or lumbar spine
RRR vs. placebo (%)












Fig. 1 The effects of a bone-forming agent on the relative fracture risk
reduction (RRR) compared with placebo. In scenario A, treatment with a
bone-forming agent induces a marked effect on fracture risk over an 18-
month exposure compared with placebo. On stopping the bone-forming
agent, the effect on fracture wanes off over a similar time interval of
18 months. In scenario C, placebo group remains untreated, whereas
the group treated with a bone-forming agent is transitioned to an inhibitor
of bone turnover which maintains the efficacy up to 4 years. In scenario
B, both the treatment and the placebo groups are treated after the exposure
with an inhibitor of bone turnover [adapted from 57]
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at least 10 years [50, 51]. In short, the prescription of a fixed
treatment interval is inappropriate in osteoporosis [52] as in
many other chronic disorders. Ironically, the ACP do not make
the same oversight in type 2 diabetes and hyperlipidemia [53].
Missed opportunity for anabolic treatment
The ACP guideline recommends that clinicians offer pharma-
cologic treatment with alendronate, risedronate, zoledronic
acid, or denosumab to reduce the risk for hip and vertebral
fractures in women who have known osteoporosis. These
drugs strengthen trabecular bone by reducing bone turnover
but do not rebuild the damaged trabecular architecture. They
have less or even no effect on strengthening cortical bone.
Perhaps the greatest deficit of the ACP guideline is the dis-
missive attitude to anabolic treatment such as teriparatide,
parathyroid hormone, and abaloparatide. The guideline ac-
knowledges that treatment with teriparatide reduces radio-
graphic vertebral and non-vertebral fractures compared with
placebo in postmenopausal osteoporotic women. The position
is predicated by the view of the ACP that there are no differ-
ences in efficacy between available interventions.
Gains in BMD following treatment with teriparatide and
abaloparatide are very substantial compared with the
bisphosphonates, SERMs, and denosumab and are expected
to be translated in terms of fracture risk reduction. Indeed, in a
head-to-head comparative trial, teriparatide has been shown to
have superior efficacy than risedronate on vertebral and clin-
ical fractures [54]. The relative risk reduction for clinical ver-
tebral fractures was 56% (95% CI = 32–71%) and that for all
clinical fractures 52% (26–68%). In a head-to-head compari-
son, abaloparatide increased BMD and reduced the risk of
non-vertebral fractures more than teriparatide and, indeed,
more rapidly [55]. Romosozumab (still an investigational
agent) followed after 12 months by alendronate for a further
year showed superior efficacy on fracture outcomes compared
with alendronate alone, albeit with some concerns over ad-
verse cardiovascular effects [56]. These observations indicate
the emergence of a rank order of the efficacy of interventions
unappreciated by the ACP.
Given that treatments with anabolic agents are limited to
18–24 months and given that efficacy will wane once treat-
ment is stopped, the real potential of the anabolic treatments is
whether their greater effect on BMD and fracture can be main-
tained with the inhibitors of bone turnover once treatment is
stopped (Fig. 1) [57]. In the case of abaloparatide, efficacy
was shown in an 18-month placebo control study with signif-
icant reductions in risk of vertebral, non-vertebral, clinical,
and major osteoporotic fractures compared with placebo
[55]. Efficacy was maintained with a subsequent 24-month
treatment with alendronate (70 mg weekly) given to patients
previously taking or abaloparatide or placebo (scenarios A
and B in Fig. 1). The relative risk reduction for vertebral frac-
ture seen in the placebo control phase of the study (RRR =
86%) was maintained in the extension phase of the trial
(RRR = 84%). A sustained effect was also seen for non-
vertebral fracture, major osteoporotic fracture, and hip fracture
risk reduction [58].
The advent of anabolic therapy that can be sustained past
the duration of exposure opens a new era in the management
of osteoporosis, particularly those patients at imminent
risk [59].
Conclusion
We recognize that several papers cited in this editorial post-
date the review of the ACP though the opinions were well
rehearsed. Notwithstanding, the ACP guideline appears out-
dated even at its time of publication, lacking in scope due to
the endorsement of treatment based upon T-scores, rather than
fracture risk assessment and in failure to adequately consider
anabolic therapies.
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